Allergy Diagnostics Market Expected to Reach $11.63 Billion by 2030, Driven by Rising Allergy Rates, Diagnostic Innovations, and Government Investments.

The global allergy diagnostics market is projected to reach USD 11.63 billion by 2030, growing at a CAGR of 10.39% from 2025. The rise in allergy rates, diagnostic innovations, and government investments drive market growth. Key players such as Thermo Fisher and Siemens are innovating to meet demand, while major growth regions include North America and Asia Pacific.

Title: Global Allergy Diagnostics Market: Trends, Innovations, and Growth Projections

The global allergy diagnostics market is poised for significant growth, projected to reach USD 11.63 billion by 2030, registering a CAGR of 10.39% from 2025. This robust expansion is driven by several key factors, including rising allergy rates, advancements in diagnostic technologies, and substantial government investments.

Allergies remain a significant public health concern worldwide, with approximately 25.7% of adults and 18.9% of children in the U.S. affected by seasonal allergies, eczema, or food allergies [1]. The prevalence of allergic conditions is further underscored by statistics from the Allergy & Asthma Network, which indicate that over 50 million Americans suffer from allergies annually [1]. The economic burden of allergic diseases is substantial, costing the U.S. healthcare system billions annually due to emergency visits, hospitalizations, and lost productivity [1].

Key players in the global allergy diagnostics market, such as Thermo Fisher Scientific, Inc., HYCOR Biomedical, and Siemens Healthcare GmbH, are innovating to meet the growing demand for accurate and accessible diagnostic solutions. For instance, Thermo Fisher Scientific expanded its allergy diagnostics offering in the U.S. in May 2022 by launching its Phadia 2500+ series for high-throughput in vitro allergy and autoimmune testing [1]. This launch supports the increasing demand for comprehensive allergy panels and molecular-level testing, addressing the growing cases of food and respiratory allergies.

The market is segmented by products and services, with consumables accounting for the largest revenue share of 63.14% in 2024 [1]. Inhaled allergens dominate the market, with a revenue share of 49.72% in 2024, driven by the high prevalence of respiratory allergies [1]. In vitro tests are preferred due to their safety, reproducibility, and ability to detect multiple allergens simultaneously [1]. Hospitals and clinics hold the highest revenue share of 37.23% in 2024, reflecting the growing integration of allergy diagnostics into outpatient services [1].

North America leads the global market, accounting for 36.53% of the revenue in 2024, due to its well-established healthcare infrastructure and strong reimbursement policies [1]. The Asia Pacific region is projected to witness the fastest growth, with a CAGR of 11.43% from 2024 to 2030, driven by factors such as urbanization, environmental pollution, and expanding access to healthcare services [1].

In conclusion, the global allergy diagnostics market is experiencing significant growth, driven by rising allergy rates, technological advancements, and government investments. Key players are innovating to meet the growing demand for accurate and accessible diagnostic solutions, with North America and the Asia Pacific region expected to lead the market growth.

References:
[1] https://www.globenewswire.com/news-release/2025/08/11/3130997/0/en/Allergy-Diagnostics-Market-Trends-Analysis-Report-2025-2030-Rising-Allergy-Rates-Diagnostic-Innovations-and-Government-Investments-Drive-Market-Growth.html